Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients.
Javier PascualJuan Miguel Gil-GilPaula Z ProszekChristoph C ZielinskiAlistair ReayManuel Ruiz BorregoRosalind J CuttsEva Ciruelos GilAndrew FeberMontserrat MuñozClaire SwiftBegoña BermejoJesus HerranzMireia MargelíAntonio Antón-TorresZsuzsanna KahánTibor CsősziYuan LiuDaniel Fernandez-GarciaIsaac Garcia-MurillasMichael HubankNicholas C TurnerMiguel MartinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with HR+/HER2- MBC harbouring plasma TP53 mutations. Early ctDNA suppression may provide treatment efficacy predictions. Further validation to fully demonstrate clinical utility of ctDNA dynamics is warranted.